These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 21783345)

  • 1. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
    Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
    Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
    Gutiérrez J; Vallejo B; Barbosa H; Pinzón J; Delgado G
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):321-8. PubMed ID: 23473403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
    Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
    Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine.
    Tempone AG; Perez D; Rath S; Vilarinho AL; Mortara RA; de Andrade HF
    J Antimicrob Chemother; 2004 Jul; 54(1):60-8. PubMed ID: 15163652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
    Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
    Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
    Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.
    Néris PL; Caldas JP; Rodrigues YK; Amorim FM; Leite JA; Rodrigues-Mascarenhas S; Barbosa-Filho JM; Rodrigues LC; Oliveira MR
    Exp Parasitol; 2013 Oct; 135(2):307-13. PubMed ID: 23891943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
    Frézard F; Michalick MS; Soares CF; Demicheli C
    Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine.
    Banerjee A; Roychoudhury J; Ali N
    J Antimicrob Chemother; 2008 Jan; 61(1):103-10. PubMed ID: 17965031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial Activity of 2-Methoxy-4H-spiro-[naphthalene-1,2'-oxiran]-4-one (Epoxymethoxy-lawsone): A Promising New Drug Candidate for Leishmaniasis Treatment.
    Oliveira LFG; Souza-Silva F; de Castro Côrtes LM; Cysne-Finkelstein L; de Souza Pereira MC; de Oliveira Junior FO; Pinho RT; Corte Real S; Bourguignon SC; Ferreira VF; Alves CR
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29642584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.